ContraFect to Chair and Participate in Virtual Superbugs & Superdrugs 2020 Conference

YONKERS, N.Y., March 30, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that Cara Cassino, MD, Chief Medical Officer and Executive Vice President of Research, will virtually chair the opening day of the 22nd Annual Superbugs & Superdrugs 2020 Conference. Dr. Cassino will also virtually present the Companya??s anti-infective portfolio and platform technology of DLAs in her talk, a??Exploring Direct Lytic Agents (DLAs) and their potential as a successful disruptive anti-infective technology.a??
Dr. Cassino will discuss the characteristics and benefits of DLAs against drug-resistant pathogens, the clinical performance of exebacase, and the ongoing Phase 3 DISRUPT (Direct Lysis of Staph aureus Resistant Pathogen Trial) superiority design study of exebacase in patients with Staph aureus bacteremia, including right-sided endocarditis. In addition, she will also highlight ContraFecta??s broad-based Gram-negative discovery program, which discovers, optimizes, and develops DLAs to specifically target the worlda??s most resistant Gram-negative pathogens.Presentation Details:Presentation Title: Exploring Direct Lytic Agents (DLAs) and their potential as a successful disruptive anti-infective technology
Time and Date: Monday, March 30, 2020, 11:30 a.m. GMTRemote Access:
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Июнь 2020    »